|
| Primary information |
|---|
| ID | 10235 |
| Therapeutic ID | Th1032 |
| Protein Name | Coagulation factor VIIa |
| Sequence | >Th1032_Coagulation_factor_VIIa
ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP
|
| Molecular Weight | 45079.1 |
| Chemical Formula | C1972H3076N560O597S28 |
| Isoelectric Point | 6.09 |
| Hydrophobicity | -0.311 |
| Melting point | 58 |
| Half-life | NA |
| Description | Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form. |
| Indication/Disease | For treatment of hemorrhagic complications in hemophilia A and B. |
| Pharmacodynamics | To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting. |
| Mechanism of Action | NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| 153 ± 29 mL/kg [children] |
| Clearance | 1375 ± 396 mL/hr [severe hemophilia A male children] |
| Categories | Amino Acids, Peptides, and Proteins, Biological Factors, Blood and Blood Forming Organs, Blood Coagulation Factors, Blood Proteins, Endopeptidases, Enzymes, Enzymes and Coenzymes, Factor VII, Factor VIIa, antagonists & inhibitors, Hemostatics, Hydrolases, Increased Coagulation Factor IX Activity, Increased Coagulation Factor X Activity, Peptide Hydrolases, Proteins, Serine Endopeptidases, Serine Proteases |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Bebulin VH (factor ix complex) |
| Target | NA |
| Brand Name | Sevenfact |
| Company | Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.) |
| Brand Description | Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.) |
| Prescribed For | treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. |
| Chemical Name | NA |
| Formulation | SEVENFACT is formulated with arginine, isoleucine, citrate, glycine, lysine and polysorbate 80. It does not contain any antimicrobial preservatives nor human or bovine plasma-derived proteins. |
| Physical Appearance | sterile, white to off-white lyophilized powder |
| Route of Administration | intravenous |
| Recommended Dosage | For mild bleeding: 75 mcg/kg repeated every 3 hours until hemostasis is achieved or Initial dose of 225 mcg/kg. If hemostasis is not achieved within 9 hours, additional 75 mcg/kg doses may be administered every 3 hours as needed to achieve hemostasis For severe Bleeding: 225 mcg/kg initially, followed if necessary 6 hours later with 75 mcg/kg every 2 hours until hemostasis is achieved. |
| Contraindication | SEVENFACT is contraindicated in known allergy to rabbits or rabbit proteins. Exposure to SEVENFACT in these patients can result in severe hypersensitivity reaction. patients with severe hypersensitivity reaction to SEVENFACT or any of its components. Exposure to SEVENFACT in these patients can result in severe hypersensitivity reaction. |
| Side Effects | headache, dizziness, infusion-site discomfort, infusion-site bleeding, infusion-related reactions, and fever |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |